« Return to News | Drug Sponsors

Takeda to integrate two subsidiaries in California

Wednesday, December 21, 2011 01:47 PM

Takeda Pharmaceutical will integrate two wholly-owned subsidiaries, Takeda San Diego (TSD) and Takeda San Francisco (TSF) on January 1, 2012. TSD will become the surviving company and change its name to Takeda California (TCAL) the same day. Keith Wilson, current president of TSD, will become the president of the new company.

TSD was established in March 2005 by acquiring U.S. Syrrx, which was applying the high-speed X-ray protein crystal structure analysis technology towards the design of potential new medicines. TSD has since contributed to the in-house development of R&D pipelines such as SYR-322, treatment for type 2 diabetes. TSF was established in November 2007 to build a sophisticated technology platform for discovery, activity enhancement, and manufacturing of antibody therapeutics.

"Establishment of TCAL has enhanced the research system in the U.S." said Paul Chapman, general manager of the pharmaceutical research division. "We will accelerate our efforts to create innovative drugs to fulfill unmet medical needs while maximizing the synergy of the research activities following the integration, and enhancing the research networks among Japan, U.S., Europe, and Asia based on the Shonan Research Center."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.